Ascendis Pharma A/S (ASND)
225.25
-1.37
(-0.60%)
USD |
NASDAQ |
Oct 16, 11:29
Ascendis Pharma SG&A Expense (TTM) : 662.10M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 662.10M |
| March 31, 2026 | 582.56M |
| December 31, 2025 | 519.00M |
| September 30, 2025 | 446.44M |
| June 30, 2025 | 390.63M |
| March 31, 2025 | 348.62M |
| December 31, 2024 | 314.76M |
| September 30, 2024 | 298.00M |
| June 30, 2024 | 290.48M |
| March 31, 2024 | 286.97M |
| December 31, 2023 | 285.88M |
| September 30, 2023 | 274.77M |
| June 30, 2023 | 266.65M |
| March 31, 2023 | 250.38M |
| December 31, 2022 | 232.18M |
| September 30, 2022 | 229.71M |
| June 30, 2022 | 214.93M |
| March 31, 2022 | 197.33M |
| December 31, 2021 | 188.99M |
| September 30, 2021 | 158.13M |
| June 30, 2021 | 132.31M |
| March 31, 2021 | 112.61M |
| December 31, 2020 | 87.48M |
| September 30, 2020 | 82.04M |
| June 30, 2020 | 72.67M |
| Date | Value |
|---|---|
| March 31, 2020 | 62.08M |
| December 31, 2019 | 54.19M |
| September 30, 2019 | 44.84M |
| June 30, 2019 | 41.62M |
| March 31, 2019 | 35.53M |
| December 31, 2018 | 29.41M |
| September 30, 2018 | 24.67M |
| June 30, 2018 | 20.10M |
| March 31, 2018 | 17.43M |
| December 31, 2017 | 15.25M |
| September 30, 2017 | 13.98M |
| June 30, 2017 | 13.59M |
| March 31, 2017 | 13.05M |
| December 31, 2016 | 12.71M |
| September 30, 2016 | 12.97M |
| June 30, 2016 | 11.57M |
| March 31, 2016 | 10.93M |
| December 31, 2015 | 7.721M |
| September 30, 2015 | 6.879M |
| June 30, 2015 | 7.389M |
| March 31, 2015 | 5.017M |
| December 31, 2014 | 5.017M |
| September 30, 2014 | 2.813M |
| June 30, 2014 | 1.534M |
| March 31, 2014 | 1.534M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| BioMarin Pharmaceutical, Inc. | 1.368B |
| Novo Nordisk A/S | 10.12B |
| Evaxion AS | 4.527M |
| Genmab A/S | 726.50M |
| Zealand Pharma A/S | 78.53M |